CG Oncology (CGON) EBT (2023 - 2026)

CG Oncology (CGON) has 4 years of EBT data on file, last reported at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 74.42% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$186.5 million (down 76.64% YoY), and the FY2025 full-year result was -$160.8 million, down 82.69% from the prior year.
• EBT for Q1 2026 stood at -$60.1 million, down from -$41.3 million in the prior quarter.
• Across five years, EBT topped out at -$8.7 million in Q1 2023 and bottomed at -$60.1 million in Q1 2026.
• The 4-year median for EBT is -$20.4 million (2024), against an average of -$27.5 million.
• Peak annual rise in EBT reached 29.72% in 2025, while the deepest fall reached 119.05% in 2025.
• A 4-year view of EBT shows it stood at -$16.6 million in 2023, then sank by 92.16% to -$31.8 million in 2024, then dropped by 29.72% to -$41.3 million in 2025, then sank by 45.68% to -$60.1 million in 2026.
• The last three EBT figures came in at -$60.1 million (Q1 2026), -$41.3 million (Q4 2025), and -$43.7 million (Q3 2025), per Business Quant data.

Peer Comparison